Should We Use PPAR Agonists to Reduce Cardiovascular Risk?
2008
Using PPAR Agonists to Lower Heart Disease Risk
publication
Evidence: moderate
Author Information
Author(s): Jennifer G. Robinson
Primary Institution: University of Iowa
Hypothesis
Can PPAR agonists effectively reduce cardiovascular risk?
Conclusion
PPAR agonists show mixed results in reducing cardiovascular events, with some increasing risks of serious adverse effects.
Supporting Evidence
- Gemfibrozil showed a significant reduction in coronary heart disease risk despite no effect on LDL.
- Pioglitazone reduced ischemic events but increased heart failure risk.
- Rosiglitazone may increase the risk of heart disease and death.
Takeaway
Some medicines that help with blood sugar and fat levels might not help your heart and could even make things worse.
Methodology
Review of randomized controlled trials and observational studies on PPAR agonists.
Potential Biases
Potential for publication bias and selective reporting in the studies reviewed.
Limitations
The studies reviewed had mixed results and varied populations, making it hard to draw clear conclusions.
Participant Demographics
Included subjects with diabetes and cardiovascular disease.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website